 |
|
|
| |
Increasing Subject Compliance in Pivotal Phase III Clinical Trials of Dolutegravir (DTG, S/GSK1349572) in HIV-Infected, ART-Naive Subjects
|
| |
| |
Reported by Jules Levin
Glasgow 2012 Nov 11-15
J Harris,1 M Bomar,2 M Campbell3
1GSK Research & Development, Stockley Park, UK; 2GSK Research & Development, Research Triangle Park, NC, USA; 3Healthcare Communications Group, El Segundo, CA, USA
|
| |
|
|
|
|
|
